At the time of writing, Rocket Pharmaceuticals Inc [RCKT] stock is trading at $25.28, up 3.52%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RCKT shares have gain 1.20% over the last week, with a monthly amount drifted -6.58%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 2, April 2024, Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia. In a post published today on Yahoo Finance, Positive, previously disclosed results from the global Phase 1/2 trial demonstrated genetic and phenotypic correction combined with hematologic stabilization extending out to 42 months after treatment with RP-L102.
From an analyst’s perspective:
Rocket Pharmaceuticals Inc [NASDAQ: RCKT] stock has seen the most recent analyst activity on April 02, 2024, when Goldman initiated its Neutral rating and assigned the stock a price target of $39. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on October 24, 2023, and set its price target to $65. On February 01, 2023, Morgan Stanley initiated with a Overweight rating and assigned a price target of $45 on the stock. Canaccord Genuity started tracking the stock assigning a Buy rating and suggested a price target of $53 on November 08, 2022. BTIG Research initiated its recommendation with a Buy and recommended $35 as its price target on November 01, 2022. Raymond James started tracking with a Outperform rating for this stock on July 08, 2022, and assigned it a price target of $22.
For the past year, the stock price of Rocket Pharmaceuticals Inc fluctuated between $14.89 and $32.53. Currently, Wall Street analysts expect the stock to reach $47.33 within the next 12 months. Rocket Pharmaceuticals Inc [NASDAQ: RCKT] shares were valued at $25.28 at the most recent close of the market. An investor can expect a potential return of 87.22% based on the average RCKT price forecast.
Analyzing the RCKT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.43, Equity is -0.51 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.59 points at the first support level, and at 23.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.76, and for the 2nd resistance point, it is at 26.24.
Rocket Pharmaceuticals Inc [RCKT] reported earnings per share of -$0.64 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.79/share, meaning a difference of $0.15 and a surprise factor of 19.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.75 per share as compared to estimates of -$0.81 per share, a difference of $0.06 representing a surprise of 7.40%.
Ratios To Look Out For
It is important to note that Rocket Pharmaceuticals Inc [NASDAQ:RCKT] has a current ratio of 7.80. As well, the Quick Ratio is 7.80, while the Cash Ratio is 1.15.
Transactions by insiders
Recent insider trading involved White Mark Andrew,, that happened on Apr 08 ’24 when 12532.0 shares were sold. Director, Makker Gotham completed a deal on Mar 21 ’24 to sell 0.27 million shares. Meanwhile, Militello John sold 2490.0 shares on Mar 21 ’24.
